TheraRadar
← Back
Data updated: Mar 29, 2026

AM GENOMICS

OncologyImmunologyMetabolic
Pharma

AM GENOMICS is a pharmaceutical company focused on Oncology, Immunology, Metabolic. Key products include CYKLX.

2025
Since
1
Drugs
-
Trials
1
Approved (2yr)

Key Drugs

CYKLX
articaine hydrochloride
· 2025

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

CYKLX 2025-08-15
Type 3 - New Dosage Form and Type 4 - New Combination
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 41%
0 drugs Phase 3: 25 Phase 2: 15 Phase 1: 70
Immunology 24%
0 drugs Phase 3: 19 Phase 2: 13 Phase 1: 13
Metabolic 18%
0 drugs Phase 3: 15 Phase 2: 4 Phase 1: 20
Cardiovascular 9%
0 drugs Phase 3: 9 Phase 2: 1 Phase 1: 4
Dermatology 8%
0 drugs Phase 3: 8 Phase 2: 3 Phase 1: 3

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Merck big-pharma
Oncology, Cardiovascular, Immunology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Cardiovascular, Metabolic
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Dermatology
Bayer big-pharma
Oncology, Cardiovascular, Dermatology, Metabolic
AstraZeneca big-pharma
Oncology, Cardiovascular, Metabolic, Immunology